$13.12
0.131%
Last update: Oct 2, 4:00 PM
$13.12
0.131%

Contineum Therapeutics (CTNM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.45 | $-0.54 | $-0.43 | $-0.51 |
| Actual | $-0.40 | $-0.39 | $-0.49 | $-0.45 |
| Surprise | +11.1% | +27.8% | -14.0% | +11.8% |
| Revenue | ||||
| Estimate | — | — | $5.0M | $5.0M |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.45 | $-0.45 | $-0.42 | $-0.41 |
| Revenue | ||||
| Consensus | $2.3M | $5.0M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $-0.40 | $-0.45 | 11.1 % |
| Q1 | May 5, 2026 | $-0.39 | $-0.54 | 27.8 % |
| Q4 | Mar 5, 2026 | $-0.49 | $-0.43 | -14.0 % |
| Q3 | Oct 30, 2025 | $-0.45 | $-0.51 | 11.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | Mar 5, 2026 | $0 | $5.00M | -100.0 % |
| Q3 | Oct 30, 2025 | $0 | $5.00M | -100.0 % |
| Q2 | Aug 5, 2025 | $0 | $6.00M | -100.0 % |